Oncocore for Cancer Patients
Providing Insights to Cancer Patients & Generating Real World Evidence
More Information
Clinical Responder Analysis
Applying Real World Evidence to Clinical Development & Outcomes research
More Information
Drug Combinations
Discovering Novel Drug Combinations within Pharma Pipelines
More Information
Indication Expansion
Prioritizing Novel Indications for Approved & Pipeline Drugs
More Information
BioXplor has developed a proprietary cancer data analytics platform to collect real world evidence and combine it with our biomedical knowledge engine via a suite of tools and algorithms that generates advanced insights for clinical development and outcomes research.
Learn more
Clinical Responders
Drug Combinations
Learn more
Indication Expansion
Learn more
Clinical Development & Outcomes Research
Patient Consent to Collect & Analyse Medical Records & Tumor Genomics Data
01
Find Clinical Trials Matched to Patient's Medical Records & Genomics Data
02
Find insights on Treatments based on Tumor Mutations
03
Find Clinicians for Second Opinions, and Enable Sharing of Medical Records
04
Find Insights on Side Effects Related to Drugs and Treatments for Side Effects
05
Access to Medical Research Literature and Clinical Trials Reports
06
ONCOCORE helps cancer patients to find the right clinical trials and insights into tumor mutations and treatments, find medical oncologists for second opinions, and support medical research to find the cures for tomorrow by improving outcomes for those cancer patients enrolling in clinical trials today.
From Our Company
Latest News
FORBES lists BioXplor Cofounder Anna O'LEary
24.06.2021
52 Women-Led Startups Driving The Future Of HealthTech And FemTech
Read More
StartUp Health Article on BioXplor
07.05.2021
Meet BioXplor, the Startup Speeding Up Novel Drug Combination Discovery Through Smarter Data Analysis
Read More
BioXplor wins EIT Health-Amgen Challenge
28.10.2020
BioXplor is the winner of the EIT Health-Amgen Challenge to ‘Identify the Right Treatment for the Right Patient in Multiple Myeloma’ as judged by the innovation managers from Takeda, Sanofi, Abbott and AstraZeneca.
Watch (1 min)
